Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deli… Read more
Arecor Therapeutics PLC (AREC) - Total Assets
Latest total assets as of June 2025: GBX5.25 Million GBX
Based on the latest financial reports, Arecor Therapeutics PLC (AREC) holds total assets worth GBX5.25 Million GBX as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arecor Therapeutics PLC - Total Assets Trend (2017–2024)
This chart illustrates how Arecor Therapeutics PLC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Arecor Therapeutics PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Arecor Therapeutics PLC's total assets of GBX5.25 Million consist of 94.4% current assets and 5.6% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 37.1% |
| Accounts Receivable | GBX2.87 Million | 33.0% |
| Inventory | GBX478.00K | 5.5% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX33.00K | 0.4% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Arecor Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arecor Therapeutics PLC's current assets represent 94.4% of total assets in 2024, an increase from 74.0% in 2017.
- Cash Position: Cash and equivalents constituted 37.1% of total assets in 2024, down from 40.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 33.0% of total assets.
Arecor Therapeutics PLC Competitors by Total Assets
Key competitors of Arecor Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Arecor Therapeutics PLC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Arecor Therapeutics PLC generates 0.58x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Arecor Therapeutics PLC is currently not profitable relative to its asset base.
Arecor Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 1.37 | 3.24 |
| Quick Ratio | 2.00 | 1.27 | 3.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX2.45 Million | GBX 1.71 Million | GBX 2.07 Million |
Arecor Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Arecor Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.58 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -43.3% |
| Total Assets | GBX8.72 Million |
| Market Capitalization | $3.33K USD |
Valuation Analysis
Below Book Valuation: The market values Arecor Therapeutics PLC's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Arecor Therapeutics PLC's assets decreased by 43.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arecor Therapeutics PLC (2017–2024)
The table below shows the annual total assets of Arecor Therapeutics PLC from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX8.72 Million | -43.28% |
| 2023-12-31 | GBX15.38 Million | -29.35% |
| 2022-12-31 | GBX21.77 Million | +4.03% |
| 2021-12-31 | GBX20.92 Million | +388.38% |
| 2020-12-31 | GBX4.28 Million | -0.51% |
| 2019-12-31 | GBX4.31 Million | -21.01% |
| 2019-05-31 | GBX5.45 Million | +163.75% |
| 2018-05-31 | GBX2.07 Million | -19.39% |
| 2017-05-31 | GBX2.56 Million | -- |